Puma Biotechnology's Q2 2025: Key Contradictions in Alisertib Strategy, In-Licensing, and Sales Growth

Alisertib dose and development strategy, in-licensing of additional products and financial strategy, data disclosure strategy and timing, in-licensing strategy and asset evaluation, reimbursement improvement impact on NERLYNX sales are the key contradictions discussed in Puma Biotechnology's latest 2025Q2 earnings call.



Revenue Growth:
- Puma Biotechnology reported total revenue of $52.3 million for Q2 2025, with product revenue net at $49.2 million, up from $43.1 million in Q1 2025.
- The growth was driven by an increase in NERLYNX bottles sold and net selling price, despite an inventory decrease at specialty pharmacies and distributors.

NERLYNX Sales and Prescriptions:
- Puma reported 2,608 bottles of NERLYNX sold in Q2 2025, an increase from 2,338 bottles in Q1 2025.
- New prescriptions decreased approximately 3% compared to Q1 2025, while total prescriptions increased by approximately 3%, indicating a shift in prescribing patterns towards higher-risk patients.

Clinical Trials and Pipeline Development:
- Puma is progressing two Phase II trials for alisertib, with promising interim data expected later in 2025 for both ALISCA-Breast and ALISCA-Lung1 trials.
- The company is exploring the potential of biomarker subgroups in correlation with efficacy, aiming to focus future clinical development in these areas.

Marketing and Sales Strategy:
- The company implemented a new marketing strategy to engage oncologists on broader patient sets where the risk of recurrence remains high and NERLYNX can play a role.
- The sales team focused on expanding HCP reach and increasing engagement during treatment decisions, leading to a 16% year-over-year and 24% quarter-over-quarter increase in call activity.